Provided by Tiger Fintech (Singapore) Pte. Ltd.

CervoMed

7.05
-0.0600-0.84%
Post-market: 7.050.00000.00%16:43 EDT
Volume:60.03K
Turnover:434.08K
Market Cap:65.23M
PE:-2.73
High:7.46
Open:7.14
Low:7.01
Close:7.11
52wk High:16.94
52wk Low:1.80
Shares:9.25M
Float Shares:4.93M
Volume Ratio:1.26
T/O Rate:1.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5788
EPS(LYR):-2.0179
ROE:-54.21%
ROA:-33.63%
PB:1.95
PE(LYR):-3.49

Loading ...

Company Profile

Company Name:
CervoMed
Exchange:
NASDAQ
Establishment Date:
2010
Employees:
15
Office Location:
20 Park Plaza,Suite 424,Boston,Massachusetts,United States
Zip Code:
02116
Fax:
- -
Introduction:
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
John Alam
Director, President and Chief Executive Officer
Robert J. Cobuzzi, Jr.
Director, Chief Operating Officer
David Quigley
Director
Frank Zavrl
Director
Jane H. Hollingsworth
Director
Jeff Poulton
Director
Joshua S. Boger
Director
Marwan Sabbagh
Director
Sylvie Gregoire
Director

Shareholders

Name
Position
John Alam
Director, President and Chief Executive Officer
Robert J. Cobuzzi, Jr.
Director, Chief Operating Officer
William R. Elder
Chief Financial Officer, General Counsel and Corporate Secretary
Kelly Blackburn
Executive Vice President, Clinical Development
Mark De Rosch
Executive Vice President, Regulatory and Government Affairs and Program Management